Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
2.310
0.00 (0.00%)
At close: Mar 6, 2026, 4:00 PM EST
2.299
-0.011 (-0.47%)
After-hours: Mar 6, 2026, 7:55 PM EST
Company Description
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer.
Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study.
Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Tempest Therapeutics, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Matthew Angel |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States | |
| Phone | 415 798 8589 |
| Website | tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U207 |
| ISIN Number | US87978U2078 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Matthew Angel Ph.D. | President, Chief Executive Officer and Director |
| Nicholas Maestas | Chief Financial Officer, Head of Corporate Strategy and Secretary |
| Justin Trojanowski CPA | Corporate Controller, Treasurer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 8-K | Current Report |
| Feb 10, 2026 | SCHEDULE 13D | Filing |
| Feb 6, 2026 | 8-K | Current Report |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Dec 31, 2025 | EFFECT | Notice of Effectiveness |
| Dec 31, 2025 | ARS | Filing |
| Dec 31, 2025 | DEF 14A | Other definitive proxy statements |